Literature DB >> 12519740

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.

Amina Jindani1, Caroline J Doré, Denis A Mitchison.   

Abstract

Colony-forming units of Mycobacterium tuberculosis in sputum were counted at 2-day intervals in 100 patients treated with 22 regimens of isoniazid, rifampin, pyrazinamide, ethambutol, or streptomycin, given alone or in combinations. The exponential fall in colony-forming units was measured by linear regression coefficients of the log counts during the initial 2-day phase of rapid, drug-determined killing and during the subsequent 12 days of much slower sterilizing activity. The regression coefficients during the first 2 days varied significantly according to the drug; the greatest effects in multiple regression analyses were due to isoniazid (p < 0.001) and rifampin (p = 0.027). The rapid kill obtained with isoniazid was unaffected by addition of other drugs, so that a change in activity after adding an unknown drug to isoniazid would not be measurable. In multiple regression analysis of the coefficients during Days 2-14, rifampin and streptomycin had significant effects (p = 0.007 and 0.006, respectively), indicating that both drugs had important sterilizing activity, streptomycin particularly early. Isoniazid and pyrazinamide had no significant effects. In analyses of combined drug regimens only, ethambutol had an effect (p = 0.01) in reverse direction to that of rifampin, suggesting it antagonized the sterilizing activity of other drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519740     DOI: 10.1164/rccm.200210-1125OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  140 in total

1.  Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.

Authors:  Andreas H Diacon; Rodney Dawson; Madeleine Hanekom; Kim Narunsky; Stefan J Maritz; Amour Venter; Peter R Donald; Christo van Niekerk; Karl Whitney; Doris J Rouse; Martino W Laurenzi; Ann M Ginsberg; Melvin K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

2.  Activity of pyrazinamide in the guinea pig model of tuberculosis.

Authors:  Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2010-12       Impact factor: 5.191

3.  Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.

Authors:  Robert S Wallis; Wesley Jakubiec; Vikas Kumar; Gabriella Bedarida; Annette Silvia; Darcy Paige; Tong Zhu; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Paul F Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 4.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

5.  Reagent precoated targets for rapid in-tissue derivatization of the anti-tuberculosis drug isoniazid followed by MALDI imaging mass spectrometry.

Authors:  M Lisa Manier; Michelle L Reyzer; Anne Goh; Veronique Dartois; Laura E Via; Clifton E Barry; Richard M Caprioli
Journal:  J Am Soc Mass Spectrom       Date:  2011-05-13       Impact factor: 3.109

6.  Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals.

Authors:  Sarah Schmidt Grant; Benjamin B Kaufmann; Nikhilesh S Chand; Nathan Haseley; Deborah T Hung
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

7.  Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis.

Authors:  Nicholas D Walter; Gregory M Dolganov; Benjamin J Garcia; William Worodria; Alfred Andama; Emmanuel Musisi; Irene Ayakaka; Tran T Van; Martin I Voskuil; Bouke C de Jong; Rebecca M Davidson; Tasha E Fingerlin; Katerina Kechris; Claire Palmer; Payam Nahid; Charles L Daley; Mark Geraci; Laurence Huang; Adithya Cattamanchi; Michael Strong; Gary K Schoolnik; John Lucian Davis
Journal:  J Infect Dis       Date:  2015-03-11       Impact factor: 5.226

8.  A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

Authors:  Elsje Pienaar; Nicholas A Cilfone; Philana Ling Lin; Véronique Dartois; Joshua T Mattila; J Russell Butler; JoAnne L Flynn; Denise E Kirschner; Jennifer J Linderman
Journal:  J Theor Biol       Date:  2014-12-09       Impact factor: 2.691

9.  Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Authors:  Sandirai Musuka; Shashikant Srivastava; Chandima Wasana Siyambalapitiyage Dona; Claudia Meek; Richard Leff; Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 10.  Revised guidelines for the diagnosis and control of tuberculosis: impact on management in the elderly.

Authors:  Paul Van den Brande
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.